SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Skye Bioscience, Inc. – ‘10-K’ for 12/31/23 – ‘XML’

On:  Thursday, 3/21/24, at 8:41pm ET   ·   As of:  3/22/24   ·   For:  12/31/23   ·   Accession #:  1516551-24-48   ·   File #:  0-55136

Previous ‘10-K’:  ‘10-K’ on 3/31/23 for 12/31/22   ·   Latest ‘10-K’:  This Filing   ·   34 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/22/24  Skye Bioscience, Inc.             10-K       12/31/23   98:12M

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.04M 
 2: EX-2.9      Agreement and Plan of Merger and Reorganization     HTML    692K 
 3: EX-3.1      Articles of Incorporation of Registrant, as         HTML     68K 
                Amended                                                          
 4: EX-4.14     Instrument Defining the Rights of Security Holders  HTML     37K 
 5: EX-21.1     Subsidiaries of the Registrant                      HTML     29K 
 6: EX-23.1     Consent of Marcum LLP                               HTML     27K 
11: EX-97.1     Compensation Recoupment Policy                      HTML     39K 
 7: EX-31.1     Certification of Principal Executive Officer        HTML     31K 
 8: EX-31.2     Certification of Principal Financial and            HTML     31K 
                Accounting Officer                                               
 9: EX-32.1     Certification of Principal Executive Officer        HTML     29K 
10: EX-32.2     Certification of Principal Financial and            HTML     29K 
                Accounting Officer                                               
17: R1          Cover                                               HTML     87K 
18: R2          Audit Information                                   HTML     32K 
19: R3          Consolidated Balance Sheets                         HTML    136K 
20: R4          Consolidated Balance Sheets (Parentheticals)        HTML     48K 
21: R5          Consolidated Statements of Operations               HTML    102K 
22: R6          Consolidated Statements of Cash Flows               HTML    171K 
23: R7          Consolidated Statements of Cash Flows               HTML     32K 
                (Parentheticals)                                                 
24: R8          Consolidated Statements of Stockholders' Equity     HTML     96K 
25: R9          Consolidated Statements of Stockholders' Equity     HTML     31K 
                (Parentheticals)                                                 
26: R10         Nature of Operations and Business Activities        HTML     37K 
27: R11         Summary of Significant Accounting Policies          HTML     84K 
28: R12         Asset Acquisitions                                  HTML     87K 
29: R13         Prepaid Expenses, Other Current Assets and Other    HTML     56K 
                Current Liabilities                                              
30: R14         Warrants and Derivative Liabilities                 HTML     93K 
31: R15         Debt                                                HTML     63K 
32: R16         Stockholders' Equity and Capitalization             HTML     50K 
33: R17         Stock-Based Compensation                            HTML     92K 
34: R18         Loss Per Share of Common Stock                      HTML     50K 
35: R19         Income Taxes                                        HTML    101K 
36: R20         Licensed Intellectual Property                      HTML     35K 
37: R21         Related Party Matters                               HTML     41K 
38: R22         Commitments and Contingencies                       HTML     52K 
39: R23         Subsequent Events                                   HTML     34K 
40: R24         Summary of Significant Accounting Policies          HTML    132K 
                (Policies)                                                       
41: R25         Asset Acquisitions (Tables)                         HTML    104K 
42: R26         Prepaid Expenses, Other Current Assets and Other    HTML     60K 
                Current Liabilities (Tables)                                     
43: R27         Warrants and Derivative Liabilities (Tables)        HTML     94K 
44: R28         Debt (Tables)                                       HTML     51K 
45: R29         Stockholders' Equity and Capitalization (Tables)    HTML     42K 
46: R30         Stock-Based Compensation (Tables)                   HTML     90K 
47: R31         Loss Per Share of Common Stock (Tables)             HTML     52K 
48: R32         Income Taxes (Tables)                               HTML     99K 
49: R33         Commitments and Contingencies (Tables)              HTML     44K 
50: R34         Nature of Operations and Business Activities        HTML     69K 
                (Details)                                                        
51: R35         Summary of Significant Accounting Policies          HTML     62K 
                (Details)                                                        
52: R36         Asset Acquisitions - BRB Acquisition - Narrative    HTML     41K 
                (Details)                                                        
53: R37         Asset Acquisitions - Schedule of BRB Acquisition    HTML     47K 
                (Details)                                                        
54: R38         Asset Acquisitions - Acquisition of Emerald Health  HTML     37K 
                Therapeutics, Inc., Narrative (Details)                          
55: R39         Asset Acquisitions - Schedule of EHT Asset          HTML     65K 
                Acquisition (Details)                                            
56: R40         Asset Acquisitions - Footnote Information From      HTML     99K 
                Schedule of Asset Acquisition (Details)                          
57: R41         Asset Acquisitions - Assumptions to Value Options   HTML     50K 
                (Details)                                                        
58: R42         Asset Acquisitions - Assumptions to Value Warrants  HTML     46K 
                (Details)                                                        
59: R43         Asset Acquisitions - Divestiture of Emerald Health  HTML     39K 
                Therapeutics Canada, Inc. - Narrative (Details)                  
60: R44         Asset Acquisitions - Divestiture of VDL -           HTML     57K 
                Narrative (Details)                                              
61: R45         Prepaid Expenses, Other Current Assets and Other    HTML     34K 
                Current Liabilities - Schedule of Prepaid Expenses               
                (Details)                                                        
62: R46         Prepaid Expenses, Other Current Assets and Other    HTML     39K 
                Current Liabilities - Schedule Of Other Current                  
                Assets (Details)                                                 
63: R47         Prepaid Expenses, Other Current Assets and Other    HTML     47K 
                Current Liabilities - Schedule of Other Current                  
                Liabilities (Details)                                            
64: R48         Warrants and Derivative Liabilities - Schedule of   HTML     74K 
                Warrants Vested and Outstanding (Details)                        
65: R49         Warrants and Derivative Liabilities - Narrative     HTML     95K 
                (Details)                                                        
66: R50         Warrants and Derivative Liabilities - Schedule of   HTML     80K 
                Input and Valuation Techniques Used to Value                     
                Warrant Liabilities (Details)                                    
67: R51         Warrants and Derivative Liabilities - Derivative    HTML     42K 
                Liabilities (Details)                                            
68: R52         Debt - Schedule of Debt (Details)                   HTML     44K 
69: R53         Debt - Narrative (Details)                          HTML    116K 
70: R54         Debt - Interest Expense (Details)                   HTML     47K 
71: R55         Stockholders? Equity and Capitalization - Reserved  HTML     53K 
                Shares of Common Stock (Details)                                 
72: R56         Stockholders? Equity and Capitalization -           HTML    121K 
                Narrative (Details)                                              
73: R57         Stock-Based Compensation - Narrative (Details)      HTML    128K 
74: R58         Stock-Based Compensation - Shares Available for     HTML     44K 
                Future Grant (Details)                                           
75: R59         Stock-Based Compensation - Summary of Option        HTML     80K 
                (Details)                                                        
76: R60         Stock-Based Compensation - Fair Value Assumptions   HTML     58K 
                of Stock Option Granted (Details)                                
77: R61         Stock-Based Compensation - Restricted Stock Awards  HTML     55K 
                (Details)                                                        
78: R62         Stock-Based Compensation - Stock-based              HTML     42K 
                Compensation Expense (Details)                                   
79: R63         Loss Per Share of Common Stock - Basic and Diluted  HTML     54K 
                Net Loss Per Share (Details)                                     
80: R64         Loss Per Share of Common Stock - Anti-dilutive      HTML     43K 
                Securities (Details)                                             
81: R65         Income Taxes - Components of Income (Loss) Before   HTML     37K 
                the Income Tax Provision (Benefit) (Details)                     
82: R66         Income Taxes - Components of Income Tax Expense     HTML     38K 
                (Details)                                                        
83: R67         Income Taxes - Narrative (Details)                  HTML     60K 
84: R68         Income Taxes - Deferred Income Tax Assets           HTML     62K 
                (Details)                                                        
85: R69         Income Taxes - Provision for Income Taxes on        HTML     62K 
                Earnings (Details)                                               
86: R70         Income Taxes - Unrecognized Tax Positions           HTML     37K 
                (Details)                                                        
87: R71         Licensed Intellectual Property (Details)            HTML     52K 
88: R72         Related Party Matters (Details)                     HTML     98K 
89: R73         Commitments and Contingencies - Narrative           HTML     72K 
                (Details)                                                        
90: R74         Commitments and Contingencies - Weighted Average    HTML     32K 
                Remaining Lease Term and Discount Rate (Details)                 
91: R75         Commitments and Contingencies - Schedule of Future  HTML     40K 
                Minimum Lease Payments (Details)                                 
92: R76         Commitments and Contingencies - Current and         HTML     33K 
                Noncurrent Portions of Operating Lease (Details)                 
93: R77         Subsequent Events (Details)                         HTML     98K 
95: XML         IDEA XML File -- Filing Summary                      XML    172K 
98: XML         XBRL Instance -- skye-20231231_htm                   XML   1.94M 
94: EXCEL       IDEA Workbook of Financial Report Info              XLSX    214K 
13: EX-101.CAL  XBRL Calculations -- skye-20231231_cal               XML    252K 
14: EX-101.DEF  XBRL Definitions -- skye-20231231_def                XML   1.16M 
15: EX-101.LAB  XBRL Labels -- skye-20231231_lab                     XML   2.11M 
16: EX-101.PRE  XBRL Presentations -- skye-20231231_pre              XML   1.51M 
12: EX-101.SCH  XBRL Schema -- skye-20231231                         XSD    268K 
96: JSON        XBRL Instance as JSON Data -- MetaLinks              561±   862K 
97: ZIP         XBRL Zipped Folder -- 0001516551-24-000048-xbrl      Zip   1.49M

‘XML’   —   IDEA XML File — Filing Summary

This Document is an IDEA XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<FilingSummary>
<Version> 3.24.1 </Version>
<ProcessingTime/>
<ReportFormat> html </ReportFormat>
<ContextCount> 320 </ContextCount>
<ElementCount> 481 </ElementCount>
<EntityCount> 1 </EntityCount>
<FootnotesReported> false </FootnotesReported>
<SegmentCount> 128 </SegmentCount>
<ScenarioCount> 0 </ScenarioCount>
<TuplesReported> false </TuplesReported>
<UnitCount> 8 </UnitCount>
<MyReports>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R1.htm </HtmlFileName>
<LongName> 0000001 - Document - Cover </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/Cover </Role>
<ShortName> Cover </ShortName>
<MenuCategory> Cover </MenuCategory>
<Position> 1 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R2.htm </HtmlFileName>
<LongName> 0000002 - Document - Audit Information </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/AuditInformation </Role>
<ShortName> Audit Information </ShortName>
<MenuCategory> Cover </MenuCategory>
<Position> 2 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R3.htm </HtmlFileName>
<LongName> 0000003 - Statement - CONSOLIDATED BALANCE SHEETS </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/CONSOLIDATEDBALANCESHEETS </Role>
<ShortName> CONSOLIDATED BALANCE SHEETS </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 3 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R4.htm </HtmlFileName>
<LongName> 0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/CONSOLIDATEDBALANCESHEETSParentheticals </Role>
<ShortName> CONSOLIDATED BALANCE SHEETS (Parentheticals) </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 4 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R5.htm </HtmlFileName>
<LongName> 0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS </Role>
<ShortName> CONSOLIDATED STATEMENTS OF OPERATIONS </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 5 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R6.htm </HtmlFileName>
<LongName> 0000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS </Role>
<ShortName> CONSOLIDATED STATEMENTS OF CASH FLOWS </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 6 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R7.htm </HtmlFileName>
<LongName> 0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parentheticals) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals </Role>
<ShortName> CONSOLIDATED STATEMENTS OF CASH FLOWS (Parentheticals) </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 7 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R8.htm </HtmlFileName>
<LongName> 0000008 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY </Role>
<ShortName> CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 8 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R9.htm </HtmlFileName>
<LongName> 0000009 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parentheticals) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParentheticals </Role>
<ShortName> CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parentheticals) </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 9 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R10.htm </HtmlFileName>
<LongName> 0000010 - Disclosure - Nature of Operations and Business Activities </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/NatureofOperationsandBusinessActivities </Role>
<ShortName> Nature of Operations and Business Activities </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 10 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R11.htm </HtmlFileName>
<LongName> 0000011 - Disclosure - Summary of Significant Accounting Policies </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/SummaryofSignificantAccountingPolicies </Role>
<ShortName> Summary of Significant Accounting Policies </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 11 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R12.htm </HtmlFileName>
<LongName> 0000012 - Disclosure - Asset Acquisitions </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/AssetAcquisitions </Role>
<ShortName> Asset Acquisitions </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 12 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R13.htm </HtmlFileName>
<LongName> 0000013 - Disclosure - Prepaid Expenses, Other Current Assets and Other Current Liabilities </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/PrepaidExpensesOtherCurrentAssetsandOtherCurrentLiabilities </Role>
<ShortName> Prepaid Expenses, Other Current Assets and Other Current Liabilities </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 13 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R14.htm </HtmlFileName>
<LongName> 0000014 - Disclosure - Warrants and Derivative Liabilities </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/WarrantsandDerivativeLiabilities </Role>
<ShortName> Warrants and Derivative Liabilities </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 14 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R15.htm </HtmlFileName>
<LongName> 0000015 - Disclosure - Debt </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/Debt </Role>
<ShortName> Debt </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 15 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R16.htm </HtmlFileName>
<LongName> 0000016 - Disclosure - Stockholders' Equity and Capitalization </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/StockholdersEquityandCapitalization </Role>
<ShortName> Stockholders' Equity and Capitalization </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 16 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R17.htm </HtmlFileName>
<LongName> 0000017 - Disclosure - Stock-Based Compensation </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/StockBasedCompensation </Role>
<ShortName> Stock-Based Compensation </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 17 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R18.htm </HtmlFileName>
<LongName> 0000018 - Disclosure - Loss Per Share of Common Stock </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/LossPerShareofCommonStock </Role>
<ShortName> Loss Per Share of Common Stock </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 18 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R19.htm </HtmlFileName>
<LongName> 0000019 - Disclosure - Income Taxes </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/IncomeTaxes </Role>
<ShortName> Income Taxes </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 19 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R20.htm </HtmlFileName>
<LongName> 0000020 - Disclosure - Licensed Intellectual Property </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/LicensedIntellectualProperty </Role>
<ShortName> Licensed Intellectual Property </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 20 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R21.htm </HtmlFileName>
<LongName> 0000021 - Disclosure - Related Party Matters </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/RelatedPartyMatters </Role>
<ShortName> Related Party Matters </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 21 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R22.htm </HtmlFileName>
<LongName> 0000022 - Disclosure - Commitments and Contingencies </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/CommitmentsandContingencies </Role>
<ShortName> Commitments and Contingencies </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 22 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R23.htm </HtmlFileName>
<LongName> 0000023 - Disclosure - Subsequent Events </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/SubsequentEvents </Role>
<ShortName> Subsequent Events </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 23 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R24.htm </HtmlFileName>
<LongName> 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/SummaryofSignificantAccountingPoliciesPolicies </Role>
<ShortName> Summary of Significant Accounting Policies (Policies) </ShortName>
<MenuCategory> Policies </MenuCategory>
<ParentRole> http://skyebioscience.com/role/SummaryofSignificantAccountingPolicies </ParentRole>
<Position> 24 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R25.htm </HtmlFileName>
<LongName> 9954472 - Disclosure - Asset Acquisitions (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/AssetAcquisitionsTables </Role>
<ShortName> Asset Acquisitions (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://skyebioscience.com/role/AssetAcquisitions </ParentRole>
<Position> 25 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R26.htm </HtmlFileName>
<LongName> 9954473 - Disclosure - Prepaid Expenses, Other Current Assets and Other Current Liabilities (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/PrepaidExpensesOtherCurrentAssetsandOtherCurrentLiabilitiesTables </Role>
<ShortName> Prepaid Expenses, Other Current Assets and Other Current Liabilities (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://skyebioscience.com/role/PrepaidExpensesOtherCurrentAssetsandOtherCurrentLiabilities </ParentRole>
<Position> 26 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R27.htm </HtmlFileName>
<LongName> 9954474 - Disclosure - Warrants and Derivative Liabilities (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/WarrantsandDerivativeLiabilitiesTables </Role>
<ShortName> Warrants and Derivative Liabilities (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://skyebioscience.com/role/WarrantsandDerivativeLiabilities </ParentRole>
<Position> 27 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R28.htm </HtmlFileName>
<LongName> 9954475 - Disclosure - Debt (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/DebtTables </Role>
<ShortName> Debt (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://skyebioscience.com/role/Debt </ParentRole>
<Position> 28 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R29.htm </HtmlFileName>
<LongName> 9954476 - Disclosure - Stockholders' Equity and Capitalization (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/StockholdersEquityandCapitalizationTables </Role>
<ShortName> Stockholders' Equity and Capitalization (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://skyebioscience.com/role/StockholdersEquityandCapitalization </ParentRole>
<Position> 29 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R30.htm </HtmlFileName>
<LongName> 9954477 - Disclosure - Stock-Based Compensation (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/StockBasedCompensationTables </Role>
<ShortName> Stock-Based Compensation (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://skyebioscience.com/role/StockBasedCompensation </ParentRole>
<Position> 30 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R31.htm </HtmlFileName>
<LongName> 9954478 - Disclosure - Loss Per Share of Common Stock (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/LossPerShareofCommonStockTables </Role>
<ShortName> Loss Per Share of Common Stock (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://skyebioscience.com/role/LossPerShareofCommonStock </ParentRole>
<Position> 31 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R32.htm </HtmlFileName>
<LongName> 9954479 - Disclosure - Income Taxes (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/IncomeTaxesTables </Role>
<ShortName> Income Taxes (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://skyebioscience.com/role/IncomeTaxes </ParentRole>
<Position> 32 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R33.htm </HtmlFileName>
<LongName> 9954480 - Disclosure - Commitments and Contingencies (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/CommitmentsandContingenciesTables </Role>
<ShortName> Commitments and Contingencies (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://skyebioscience.com/role/CommitmentsandContingencies </ParentRole>
<Position> 33 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R34.htm </HtmlFileName>
<LongName> 9954481 - Disclosure - Nature of Operations and Business Activities (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/NatureofOperationsandBusinessActivitiesDetails </Role>
<ShortName> Nature of Operations and Business Activities (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://skyebioscience.com/role/NatureofOperationsandBusinessActivities </ParentRole>
<Position> 34 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R35.htm </HtmlFileName>
<LongName> 9954482 - Disclosure - Summary of Significant Accounting Policies (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/SummaryofSignificantAccountingPoliciesDetails </Role>
<ShortName> Summary of Significant Accounting Policies (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://skyebioscience.com/role/SummaryofSignificantAccountingPoliciesPolicies </ParentRole>
<Position> 35 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R36.htm </HtmlFileName>
<LongName> 9954483 - Disclosure - Asset Acquisitions - BRB Acquisition - Narrative (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/AssetAcquisitionsBRBAcquisitionNarrativeDetails </Role>
<ShortName> Asset Acquisitions - BRB Acquisition - Narrative (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 36 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R37.htm </HtmlFileName>
<LongName> 9954484 - Disclosure - Asset Acquisitions - Schedule of BRB Acquisition (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/AssetAcquisitionsScheduleofBRBAcquisitionDetails </Role>
<ShortName> Asset Acquisitions - Schedule of BRB Acquisition (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 37 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R38.htm </HtmlFileName>
<LongName> 9954485 - Disclosure - Asset Acquisitions - Acquisition of Emerald Health Therapeutics, Inc., Narrative (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/AssetAcquisitionsAcquisitionofEmeraldHealthTherapeuticsIncNarrativeDetails </Role>
<ShortName> Asset Acquisitions - Acquisition of Emerald Health Therapeutics, Inc., Narrative (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 38 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R39.htm </HtmlFileName>
<LongName> 9954486 - Disclosure - Asset Acquisitions - Schedule of EHT Asset Acquisition (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/AssetAcquisitionsScheduleofEHTAssetAcquisitionDetails </Role>
<ShortName> Asset Acquisitions - Schedule of EHT Asset Acquisition (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 39 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R40.htm </HtmlFileName>
<LongName> 9954487 - Disclosure - Asset Acquisitions - Footnote Information From Schedule of Asset Acquisition (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/AssetAcquisitionsFootnoteInformationFromScheduleofAssetAcquisitionDetails </Role>
<ShortName> Asset Acquisitions - Footnote Information From Schedule of Asset Acquisition (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 40 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R41.htm </HtmlFileName>
<LongName> 9954488 - Disclosure - Asset Acquisitions - Assumptions to Value Options (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/AssetAcquisitionsAssumptionstoValueOptionsDetails </Role>
<ShortName> Asset Acquisitions - Assumptions to Value Options (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 41 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R42.htm </HtmlFileName>
<LongName> 9954489 - Disclosure - Asset Acquisitions - Assumptions to Value Warrants (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/AssetAcquisitionsAssumptionstoValueWarrantsDetails </Role>
<ShortName> Asset Acquisitions - Assumptions to Value Warrants (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 42 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R43.htm </HtmlFileName>
<LongName> 9954490 - Disclosure - Asset Acquisitions - Divestiture of Emerald Health Therapeutics Canada, Inc. - Narrative (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/AssetAcquisitionsDivestitureofEmeraldHealthTherapeuticsCanadaIncNarrativeDetails </Role>
<ShortName> Asset Acquisitions - Divestiture of Emerald Health Therapeutics Canada, Inc. - Narrative (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 43 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R44.htm </HtmlFileName>
<LongName> 9954491 - Disclosure - Asset Acquisitions - Divestiture of VDL - Narrative (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/AssetAcquisitionsDivestitureofVDLNarrativeDetails </Role>
<ShortName> Asset Acquisitions - Divestiture of VDL - Narrative (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 44 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R45.htm </HtmlFileName>
<LongName> 9954492 - Disclosure - Prepaid Expenses, Other Current Assets and Other Current Liabilities - Schedule of Prepaid Expenses (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/PrepaidExpensesOtherCurrentAssetsandOtherCurrentLiabilitiesScheduleofPrepaidExpensesDetails </Role>
<ShortName> Prepaid Expenses, Other Current Assets and Other Current Liabilities - Schedule of Prepaid Expenses (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 45 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R46.htm </HtmlFileName>
<LongName> 9954493 - Disclosure - Prepaid Expenses, Other Current Assets and Other Current Liabilities - Schedule Of Other Current Assets (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/PrepaidExpensesOtherCurrentAssetsandOtherCurrentLiabilitiesScheduleOfOtherCurrentAssetsDetails </Role>
<ShortName> Prepaid Expenses, Other Current Assets and Other Current Liabilities - Schedule Of Other Current Assets (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 46 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R47.htm </HtmlFileName>
<LongName> 9954494 - Disclosure - Prepaid Expenses, Other Current Assets and Other Current Liabilities - Schedule of Other Current Liabilities (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/PrepaidExpensesOtherCurrentAssetsandOtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails </Role>
<ShortName> Prepaid Expenses, Other Current Assets and Other Current Liabilities - Schedule of Other Current Liabilities (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 47 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R48.htm </HtmlFileName>
<LongName> 9954495 - Disclosure - Warrants and Derivative Liabilities - Schedule of Warrants Vested and Outstanding (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/WarrantsandDerivativeLiabilitiesScheduleofWarrantsVestedandOutstandingDetails </Role>
<ShortName> Warrants and Derivative Liabilities - Schedule of Warrants Vested and Outstanding (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 48 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R49.htm </HtmlFileName>
<LongName> 9954496 - Disclosure - Warrants and Derivative Liabilities - Narrative (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/WarrantsandDerivativeLiabilitiesNarrativeDetails </Role>
<ShortName> Warrants and Derivative Liabilities - Narrative (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 49 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R50.htm </HtmlFileName>
<LongName> 9954497 - Disclosure - Warrants and Derivative Liabilities - Schedule of Input and Valuation Techniques Used to Value Warrant Liabilities (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/WarrantsandDerivativeLiabilitiesScheduleofInputandValuationTechniquesUsedtoValueWarrantLiabilitiesDetails </Role>
<ShortName> Warrants and Derivative Liabilities - Schedule of Input and Valuation Techniques Used to Value Warrant Liabilities (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 50 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R51.htm </HtmlFileName>
<LongName> 9954498 - Disclosure - Warrants and Derivative Liabilities - Derivative Liabilities (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/WarrantsandDerivativeLiabilitiesDerivativeLiabilitiesDetails </Role>
<ShortName> Warrants and Derivative Liabilities - Derivative Liabilities (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 51 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R52.htm </HtmlFileName>
<LongName> 9954499 - Disclosure - Debt - Schedule of Debt (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/DebtScheduleofDebtDetails </Role>
<ShortName> Debt - Schedule of Debt (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 52 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R53.htm </HtmlFileName>
<LongName> 9954500 - Disclosure - Debt - Narrative (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/DebtNarrativeDetails </Role>
<ShortName> Debt - Narrative (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 53 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R54.htm </HtmlFileName>
<LongName> 9954501 - Disclosure - Debt - Interest Expense (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/DebtInterestExpenseDetails </Role>
<ShortName> Debt - Interest Expense (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 54 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R55.htm </HtmlFileName>
<LongName> 9954502 - Disclosure - Stockholders??? Equity and Capitalization - Reserved Shares of Common Stock (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/StockholdersEquityandCapitalizationReservedSharesofCommonStockDetails </Role>
<ShortName> Stockholders??? Equity and Capitalization - Reserved Shares of Common Stock (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 55 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R56.htm </HtmlFileName>
<LongName> 9954503 - Disclosure - Stockholders??? Equity and Capitalization - Narrative (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/StockholdersEquityandCapitalizationNarrativeDetails </Role>
<ShortName> Stockholders??? Equity and Capitalization - Narrative (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 56 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R57.htm </HtmlFileName>
<LongName> 9954504 - Disclosure - Stock-Based Compensation - Narrative (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/StockBasedCompensationNarrativeDetails </Role>
<ShortName> Stock-Based Compensation - Narrative (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 57 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R58.htm </HtmlFileName>
<LongName> 9954505 - Disclosure - Stock-Based Compensation - Shares Available for Future Grant (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/StockBasedCompensationSharesAvailableforFutureGrantDetails </Role>
<ShortName> Stock-Based Compensation - Shares Available for Future Grant (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 58 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R59.htm </HtmlFileName>
<LongName> 9954506 - Disclosure - Stock-Based Compensation - Summary of Option (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/StockBasedCompensationSummaryofOptionDetails </Role>
<ShortName> Stock-Based Compensation - Summary of Option (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 59 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R60.htm </HtmlFileName>
<LongName> 9954507 - Disclosure - Stock-Based Compensation - Fair Value Assumptions of Stock Option Granted (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/StockBasedCompensationFairValueAssumptionsofStockOptionGrantedDetails </Role>
<ShortName> Stock-Based Compensation - Fair Value Assumptions of Stock Option Granted (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 60 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R61.htm </HtmlFileName>
<LongName> 9954508 - Disclosure - Stock-Based Compensation - Restricted Stock Awards (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/StockBasedCompensationRestrictedStockAwardsDetails </Role>
<ShortName> Stock-Based Compensation - Restricted Stock Awards (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 61 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R62.htm </HtmlFileName>
<LongName> 9954509 - Disclosure - Stock-Based Compensation - Stock-based Compensation Expense (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/StockBasedCompensationStockbasedCompensationExpenseDetails </Role>
<ShortName> Stock-Based Compensation - Stock-based Compensation Expense (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 62 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R63.htm </HtmlFileName>
<LongName> 9954510 - Disclosure - Loss Per Share of Common Stock - Basic and Diluted Net Loss Per Share (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/LossPerShareofCommonStockBasicandDilutedNetLossPerShareDetails </Role>
<ShortName> Loss Per Share of Common Stock - Basic and Diluted Net Loss Per Share (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 63 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R64.htm </HtmlFileName>
<LongName> 9954511 - Disclosure - Loss Per Share of Common Stock - Anti-dilutive Securities (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/LossPerShareofCommonStockAntidilutiveSecuritiesDetails </Role>
<ShortName> Loss Per Share of Common Stock - Anti-dilutive Securities (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 64 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R65.htm </HtmlFileName>
<LongName> 9954512 - Disclosure - Income Taxes - Components of Income (Loss) Before the Income Tax Provision (Benefit) (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/IncomeTaxesComponentsofIncomeLossBeforetheIncomeTaxProvisionBenefitDetails </Role>
<ShortName> Income Taxes - Components of Income (Loss) Before the Income Tax Provision (Benefit) (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 65 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R66.htm </HtmlFileName>
<LongName> 9954513 - Disclosure - Income Taxes - Components of Income Tax Expense (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails </Role>
<ShortName> Income Taxes - Components of Income Tax Expense (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 66 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R67.htm </HtmlFileName>
<LongName> 9954514 - Disclosure - Income Taxes - Narrative (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/IncomeTaxesNarrativeDetails </Role>
<ShortName> Income Taxes - Narrative (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 67 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R68.htm </HtmlFileName>
<LongName> 9954515 - Disclosure - Income Taxes - Deferred Income Tax Assets (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails </Role>
<ShortName> Income Taxes - Deferred Income Tax Assets (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 68 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R69.htm </HtmlFileName>
<LongName> 9954516 - Disclosure - Income Taxes - Provision for Income Taxes on Earnings (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsDetails </Role>
<ShortName> Income Taxes - Provision for Income Taxes on Earnings (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 69 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R70.htm </HtmlFileName>
<LongName> 9954517 - Disclosure - Income Taxes - Unrecognized Tax Positions (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/IncomeTaxesUnrecognizedTaxPositionsDetails </Role>
<ShortName> Income Taxes - Unrecognized Tax Positions (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 70 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R71.htm </HtmlFileName>
<LongName> 9954518 - Disclosure - Licensed Intellectual Property (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/LicensedIntellectualPropertyDetails </Role>
<ShortName> Licensed Intellectual Property (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://skyebioscience.com/role/LicensedIntellectualProperty </ParentRole>
<Position> 71 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R72.htm </HtmlFileName>
<LongName> 9954519 - Disclosure - Related Party Matters (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/RelatedPartyMattersDetails </Role>
<ShortName> Related Party Matters (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://skyebioscience.com/role/RelatedPartyMatters </ParentRole>
<Position> 72 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R73.htm </HtmlFileName>
<LongName> 9954520 - Disclosure - Commitments and Contingencies - Narrative (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/CommitmentsandContingenciesNarrativeDetails </Role>
<ShortName> Commitments and Contingencies - Narrative (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 73 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R74.htm </HtmlFileName>
<LongName> 9954521 - Disclosure - Commitments and Contingencies - Weighted Average Remaining Lease Term and Discount Rate (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/CommitmentsandContingenciesWeightedAverageRemainingLeaseTermandDiscountRateDetails </Role>
<ShortName> Commitments and Contingencies - Weighted Average Remaining Lease Term and Discount Rate (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 74 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R75.htm </HtmlFileName>
<LongName> 9954522 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails </Role>
<ShortName> Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 75 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R76.htm </HtmlFileName>
<LongName> 9954523 - Disclosure - Commitments and Contingencies - Current and Noncurrent Portions of Operating Lease (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/CommitmentsandContingenciesCurrentandNoncurrentPortionsofOperatingLeaseDetails </Role>
<ShortName> Commitments and Contingencies - Current and Noncurrent Portions of Operating Lease (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 76 </Position>
</Report>
<Report instance="skye-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R77.htm </HtmlFileName>
<LongName> 9954524 - Disclosure - Subsequent Events (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://skyebioscience.com/role/SubsequentEventsDetails </Role>
<ShortName> Subsequent Events (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://skyebioscience.com/role/SubsequentEvents </ParentRole>
<Position> 77 </Position>
</Report>
<Report>
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<LongName> All Reports </LongName>
<ReportType> Book </ReportType>
<ShortName> All Reports </ShortName>
</Report>
</MyReports>
<Logs>
<Log type="Warning"> [dq-0542-Deprecated-Concept] Concept AccountingStandardsUpdate202110Member in us-gaap/2023 used in 4 facts was deprecated in us-gaap/2024 as of 2024 and should not be used. skye-20231231.htm 4 </Log>
<Log type="Warning"> [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityCommonStockSharesOutstanding, skye:DebtInstrumentMaturityExtension, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 - skye-20231231.htm 4 </Log>
<Log type="Warning"> [DQC.US.0091.9376] The element us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate with a value of 87.400000 has a value greater than a 1,000 percent. Percentage items should have a value that are generally between 0 and 1. In XBRL a value of 1 is equal to 100%. Please review the value of the element to ensure that it is scaled correctly. For example 200 basis points should be reported as 0.02. The properties of this us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate fact are: Context: c-232 Unit: number. - skye-20231231.htm 4 - skye-20231231.htm 4 </Log>
<Log type="Warning"> [DQC.US.0091.9376] The element us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate with a value of 87.900000 has a value greater than a 1,000 percent. Percentage items should have a value that are generally between 0 and 1. In XBRL a value of 1 is equal to 100%. Please review the value of the element to ensure that it is scaled correctly. For example 200 basis points should be reported as 0.02. The properties of this us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate fact are: Context: c-233 Unit: number. - skye-20231231.htm 4 - skye-20231231.htm 4 </Log>
</Logs>
<InputFiles>
<File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="skye-20231231.htm"> skye-20231231.htm </File>
<File> skye-20231231.xsd </File>
<File> skye-20231231_cal.xml </File>
<File> skye-20231231_def.xml </File>
<File> skye-20231231_lab.xml </File>
<File> skye-20231231_pre.xml </File>
</InputFiles>
<SupplementalFiles>
<File> skye-20231231_g1.jpg </File>
</SupplementalFiles>
<BaseTaxonomies>
<BaseTaxonomy items="815"> http://fasb.org/us-gaap/2023 </BaseTaxonomy>
<BaseTaxonomy items="36"> http://xbrl.sec.gov/dei/2023 </BaseTaxonomy>
</BaseTaxonomies>
<HasPresentationLinkbase> true </HasPresentationLinkbase>
<HasCalculationLinkbase> true </HasCalculationLinkbase>
</FilingSummary>

6 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/10/24  Skye Bioscience, Inc.             S-3                    6:1.3M                                   Workiva Inc Wde… FA01/FA
 5/10/24  Skye Bioscience, Inc.             S-3                    4:333K                                   Workiva Inc Wde… FA01/FA
 5/10/24  Skye Bioscience, Inc.             10-Q        3/31/24   59:4.2M
 4/24/24  Skye Bioscience, Inc.             POS AM                 4:404K                                   Workiva Inc Wde… FA01/FA
 4/04/24  Skye Bioscience, Inc.             S-1/A                 87:9.1M                                   Workiva Inc Wde… FA01/FA
 3/27/24  Skye Bioscience, Inc.             S-1                   90:12M                                    Workiva Inc Wde… FA01/FA

28 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

12/05/23  Skye Bioscience, Inc.             8-K:1,9    11/29/23   13:743K
11/14/23  Skye Bioscience, Inc.             10-Q        9/30/23   73:6.7M
10/17/23  Skye Bioscience, Inc.             DEF 14C    10/16/23    1:563K
 8/21/23  Skye Bioscience, Inc.             8-K:1,2,3,5 8/15/23   21:34M
 3/31/23  Skye Bioscience, Inc.             10-K       12/31/22   97:10M
 2/15/23  Skye Bioscience, Inc.             8-K:1,2,8,9 2/09/23   12:224K
 1/27/23  Skye Bioscience, Inc.             8-K:1,7,9   1/26/23   11:240K
12/19/22  Skye Bioscience, Inc.             8-K:1,9    12/14/22   11:257K
11/14/22  Skye Bioscience, Inc.             10-Q        9/30/22   74:9.8M
10/19/22  Skye Bioscience, Inc.             8-K:1,2,9  10/14/22   12:293K
 8/31/22  Skye Bioscience, Inc.             DEFM14A                1:5.3M
 7/21/22  Skye Bioscience, Inc.             8-K:1,9     7/15/22   11:201K
 6/17/22  Skye Bioscience, Inc.             8-K:1,4,5,9 6/14/22   12:218K
 5/12/22  Skye Bioscience, Inc.             8-K:1,3,5,8 5/11/22   14:1.6M
 3/28/22  Skye Bioscience, Inc.             10-K       12/31/21   84:10M
10/06/21  Skye Bioscience, Inc.             8-K:5,8,9  10/05/21   12:276K
 9/28/21  Skye Bioscience, Inc.             8-K:1,8,9   9/27/21   19:763K                                   Pubco Reporting … Inc/FA
 9/15/21  Skye Bioscience, Inc.             8-K:5,8,9   9/14/21   12:23M                                    Workiva Inc Wde… FA01/FA
 8/06/21  Skye Bioscience, Inc.             10-Q        6/30/21   57:7.9M                                   Workiva Inc Wde… FA01/FA
 7/22/21  Skye Bioscience, Inc.             8-K:1,3,9   7/21/21    3:151K                                   Pubco Reporting … Inc/FA
 3/02/21  Skye Bioscience, Inc.             10-K       12/31/20   77:10M                                    Pubco Reporting … Inc/FA
 8/12/20  Skye Bioscience, Inc.             8-K:5,8,9   8/07/20    5:143K                                   Pubco Reporting … Inc/FA
 8/05/20  Skye Bioscience, Inc.             8-K:1,8,9   7/31/20    5:377K                                   Pubco Reporting … Inc/FA
11/21/19  Skye Bioscience, Inc.             8-K:1,8,9  11/21/19    4:270K                                   Pubco Reporting … Inc/FA
 1/22/18  Skye Bioscience, Inc.             8-K:1,3,5,7 1/19/18    4:420K                                   Pubco Reporting … Inc/FA
 8/20/15  Skye Bioscience, Inc.             8-K:1,5,7,9 8/19/15    6:2.1M                                   Pubco Reporting … Inc/FA
 1/12/15  Skye Bioscience, Inc.             8-K:5,7,9   1/09/15    3:107K                                   PubCo Reporting … Inc/FA
11/03/14  Skye Bioscience, Inc.             8-K:1,2,3,410/31/14   28:8.5M                                   PubCo Reporting … Inc/FA
↑Top
Filing Submission 0001516551-24-000048   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Thu., May 16, 3:04:06.2pm ET